Bioengineered Patient Trials Forum

/

You’re Invited to Methuselah Foundation’s Bioengineered Patient Trials Forum

Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, highlighting the crucial role of biopharmaceutical innovation according to a study published by Health Affairs. Life expectancy increased 3.3 years during that time period.

Animal testing has played an important part of the R&D pipeline for new medicines but continues to limit effectiveness. The result? Years of delay and billions of dollars wasted. Developing a new medicine takes an average of 10+ years and costs an average of $2.6 billion. This could be drastically reduced.

We invite you to join our Bioengineered Patient Trials Forum on Thursday, March 17th at 12:00pm ET. We will discuss key milestones in creating human equivalency trial technologies using engineered tissue rather than animal models.

The Bioengineered Patient Trials initiative from the Methuselah Foundation aims to accelerate new drug and therapy trial technologies to help extend healthy human lifespan. By creating a milestone-driven development framework for bioengineered tissue technologies we aim to advance three goals:

  1. Improve the efficiency of the drug development process

  2. Remove the need for animal testing in medical trials and drug development

  3. Reduce the risk to patients in clinical trials.

To achieve these goals, we hope to define a set of Bioengineered Trial Technology Competency Levels that identify key milestones in creating human equivalency trial technologies using engineered tissue rather than animal models or human patients. Using these levels as benchmarks, we aim to organize, facilitate, and accelerate solutions to each milestone through a series of incentive prizes co-funded by the Methuselah Foundation and government partners.

We are reaching out to engage the scientific community, government leaders, and healthcare industry in discussing and examining the definition of these competency levels and potential future incentive prize programs. With your input, we aim to define the set of competency levels to use as benchmarks in understanding Bioengineered Trial Technologies and identify key metrics and objectives for future incentive prizes to accelerate these solutions.

Help us change the status quo. This is a public discussion, so please forward to any interested friends or family. Excited to see you there!